




Kidney Week 2026
Exhibitor Spotlight
Theater #1

**BEYOND B CELLS: PIONEERING PLASMABLAST AND
PLASMA CELL TARGETING IN IgA NEPHROPATHY AND
PRIMARY MEMBRANOUS NEPHROPATHY**

Join our presentation on
Friday, October 23, 2026 from 12:00 – 12:45 pm,
Exhibit Hall A, Colorado Convention Center, Denver, CO

Immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN) continue to impose a significant burden on patients worldwide, with important unmet needs remaining despite recent therapeutic advances.^{1,2} Growing evidence identifies CD38⁺ plasmablasts and CD38⁺ plasma cells as key sources of pathogenic antibodies in IgAN and PMN, highlighting these cells as promising therapeutic targets.^{1,3-5} **Join this presentation** to explore **persistent unmet needs**, examine the role of **CD38⁺ plasmablasts and plasma cells** in disease pathogenesis, and review **emerging clinical data on an investigational CD38-targeted therapy**.



Sayna Norouzi, MD, FASN
Loma Linda University Medical Center



Brad H. Rovin, MD, FASN, FACP
Ohio State University College of Medicine



Vlado Perkovic, MBBS, PhD
University of New South Wales

1. Maixnerova D, et al. *J Clin Med*. 2022;11(10):2810; 2. Ronco P, et al. *Nat Rev Dis Primers*. 2021;7(1):69; 3. Nihei Y, et al. *Sci Adv*. 2023;9(12):eadd6734; 4. Cantarelli C, et al. *Kidney Int Rep*. 2020;5(10):1764-1776; 5. Rovin BH, et al. *Kidney Int Rep*. 2024;9(9):2635-2647.